Spending more time researching charity picks than short possibilities, but some of the latter remain on my radar, and even in my portfolio. For now I will throw out some names and brief theses for interested biofreaks, and will come back with details later.
ECYT: still hasn't raised. Shares have come back some. Have some Dec 6 naked short calls expiring in a couple of days. Would consider another entry if it got over $5.
ZYNE: just closed a position, more for allocation reasons than lack of conviction. Data for its CBD drug for epilepsy looks shaky compared to GWPH, which is also ahead in time. Would likely re-enter the short if it pokes over $12.
GALT: Have a current position, which is about even. Highly spun NASH failure. With MDGL and others sporting much better data, this is a warrant laden financing waiting to happen. I consider it shortable right here and now.
CUR: another highly spun failure, it managed to ride SAGE's coattails for a while. I have a position that will close in a couple of days. Shortable over $2.
SYRS: attempting to claim its platform is worth something despite miserable failure of lead compound at ASH (CD38 claims grasping at straws, data does not currently back the idea up; take no position if you don't get this). Have a position. This has been very volatile the last few days. A spike over $10 is a short, IMO. Trading almost 4x cash, but not in immediate need.
TXMD: Might succeed in clinic, per recent data, but no catalysts for a year or more, and facing a market of fairly effective generics.
OTIC: still elevated, but can't even remember my thesis here.
Cheers, Tuck |
